Thyroid Function, Thyroid Immunoglobulin Status, and Urinary Iodine Excretion after Enteral Contrast-Agent Administration by Endoscopic Retrograde Cholangiopancreatography

Endoscopy ◽  
2001 ◽  
Vol 33 (3) ◽  
pp. 245-252 ◽  
Author(s):  
Fassbender ◽  
Vogel ◽  
Doppl ◽  
Stracke ◽  
Bretzel ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Thyroid Function ◽  
Endoscopic Retrograde Cholangiopancreatography ◽  
Urinary Iodine ◽  
Urinary Iodine Excretion ◽  
Endoscopic Retrograde ◽  
Iodine Excretion ◽  
Contrast Agent Administration

scholarly journals Urinary Iodine Excretion and Serum Thyroid Function in Adults After Iodinated Contrast Administration

Thyroid ◽  
2015 ◽  
Vol 25 (5) ◽  
pp. 471-477 ◽  
Author(s):  
Sun Y. Lee ◽  
Donny L.F. Chang ◽  
Xuemei He ◽  
Elizabeth N. Pearce ◽  
Lewis E. Braverman ◽  
...  
Keyword(s):  
Thyroid Function ◽  
Urinary Iodine ◽  
Urinary Iodine Excretion ◽  
Contrast Administration ◽  
Iodinated Contrast ◽  
Iodine Excretion

scholarly journals Serum TSH and serum thyroid peroxidase antibody fluctuate in parallel and high urinary iodine excretion predicts subsequent thyroid failure in a 1-year study of patients with untreated subclinical hypothyroidism

2008 ◽  
Vol 158 (2) ◽  
pp. 209-215 ◽  
Author(s):  
Jesper Karmisholt ◽  
Peter Laurberg
Keyword(s):  
Thyroid Function ◽  
Subclinical Hypothyroidism ◽  
Urinary Iodine ◽  
Time Shift ◽  
Urinary Iodine Excretion ◽  
Thyroid Peroxidase ◽  
Thyroid Peroxidase Antibody ◽  
Iodine Excretion ◽  
Symptoms And Signs ◽  
Serum Tsh

ObjectiveTo explore the possibility of predicting decline or improvement in thyroid function over 1 year, and to investigate the correlations of serum TSH (s-TSH) with hypothyroidism-related symptoms and signs, serum thyroid peroxidase antibody (s-TPO-Ab) and urinary iodine excretion in individual patients with untreated subclinical hypothyroidism (SH).DesignMonthly repeated measurement study without intervention.MethodsTwenty-one patients without former thyroid disease who had been identified with s-TSH between 5 and 12 mU/l and normal serum thyroxine (s-T4) at two occasions were enrolled. Subsequently, 13 monthly measurements of s-TSH, hypothyroidism-related symptoms and signs, serum free T4, s-TPO-Ab and urinary iodine excretion were performed.ResultsOver the study year, s-TSH increased significantly in 5 patients, 16 had unchanged s-TSH, whereas none improved. From clinical and biochemical inclusion data, it was not possible to predict who would later increase in s-TSH. In individual patients, a highly significant correlation between s-TSH and s-TPO-Ab was found (r=0.37, P<0.0001) and also between s-TSH and urinary iodine excretion (r=0.14, P=0.034). No correlation between s-TSH and clinical symptoms and signs was observed. Time shift showed best correlation between s-TSH and s-TPO-Ab measured at the same time point, whereas urinary iodine excretion correlated best to s-TSH and s-TPO-Ab obtained 1 month later.ConclusionAt the time of inclusion, it was not possible to identify the 24% of SH patients who would show deterioration in thyroid function over the following year. Impairment in thyroid function varied in parallel with thyroid autoimmunity, whereas high urinary iodine excretion predicted high s-TSH and s-TPO-Ab 1 month later.

scholarly journals Urinary iodine excretion and thyroid function status in school age children of hilly and plain regions of Eastern Nepal

2015 ◽  
Vol 8 (1) ◽  
Author(s):  
Prem Raj Shakya ◽  
Basanta Gelal ◽  
Binod Kumar Lal Das ◽  
Madhab Lamsal ◽  
Paras Kumar Pokharel ◽  
...  
Keyword(s):  
Thyroid Function ◽  
Urinary Iodine ◽  
School Age Children ◽  
Urinary Iodine Excretion ◽  
School Age ◽  
Iodine Excretion

Earliest prevention of endemic goiter by iodine supplementation during pregnancy

1996 ◽  
Vol 134 (4) ◽  
pp. 443-448 ◽  
Author(s):  
Klaus Peter Liesenkötter ◽  
Wolfgang Göpel ◽  
Ulrich Bogner ◽  
Barbara Stach ◽  
Annette Grüters
Keyword(s):  
Thyroid Function ◽  
Iodine Deficiency ◽  
Endemic Goiter ◽  
Urinary Iodine ◽  
Thyroid Volume ◽  
Urinary Iodine Excretion ◽  
Thyroid Peroxidase ◽  
Iodine Supplementation ◽  
Iodine Excretion ◽  
Maternal Thyroid

Liesenkötter KP, Göpel W, Bogner U, Stach B, Grüters A. Earliest prevention of endemic goiter by iodine supplementation during pregnancy. Eur J Endocrinol 1996;134:443–8. ISSN 0804–4643 During pregnancy complex changes of maternal thyroid function occur and they are influenced by the maternal iodine supply. It has been demonstrated that with decreasing iodine supply maternal goiter and hypothyroxinemia as well as fetal and neonatal hypothyroidism become more prevalent. Therefore iodine supplementation during pregnancy is now strongly recommended also in areas of moderate iodine deficiency. To monitor the success of iodine supplementation and its theoretical risk of increasing the frequency of thyroid autoantibodies, we have investigated the thyroid volume, thyroid function, urinary iodine excretion and antibodies to thyroid peroxidase at 10–12 weeks of gestation and postpartum in 38 mothers receiving 300 μg potassium iodide/day and in 70 mothers without iodine supplementation. In all of their newborns thyroid volume was determined by ultrasound. The thyrotropin (TSH) levels and antibodies to thyroid peroxidase (TPO-ab) in the neonates were measured in dried blood spots on filter paper from their newborn screening. Urinary iodine excretion was increased significantly after iodine supplementation in mothers (p < 0.001) and their newborns (<0.05). No hypo- or hyperthyroidism was observed in the mothers or newborns. Interestingly, no difference of maternal thyroid volumes was observed between the two groups after pregnancy, but the volumes of the thyroid glands in newborns of mothers who received iodine were significantly (p < 0.004) lower (0.7 ± 0.4 ml) than in the control group (1.5 ± 1.1 ml). There was no change in the frequency of TPO-ab in either group after pregnancy. In four mothers transplacental passage of these antibodies was documented by positive measurement in the blood sample of the newborn. This study documents that iodine supplementation during pregnancy in an area of moderate iodine deficiency results in a lower size of neonatal thyroid volume and that this supplementation was not accompanied by an increase in the frequency of TPO-ab. Klaus Peter Liesenkötter, Kinderklinik Kaiserin Auguste Victoria Haus (KAVH), Virchow-Klinikum der Medizinische Fakultät der Humboldt-Universität zu Berlin, Heubnerweg 6, 14059 Berlin, Germany

Systemic iodine absorption during endoscopic application of radiographic contrast agents for endoscopic retrograde cholangiopancreaticography

1994 ◽  
Vol 130 (5) ◽  
pp. 498-501 ◽  
Author(s):  
K Mann ◽  
J Rendl ◽  
R Busley ◽  
B Sailer ◽  
S Seybold ◽  
...  
Keyword(s):  
Contrast Agents ◽  
Urinary Iodine ◽  
Serum Levels ◽  
Urinary Iodine Excretion ◽  
Endoscopic Retrograde ◽  
Total Iodine ◽  
Endoscopic Retrograde Cholangiopancreaticography ◽  
Iodine Excretion ◽  
Endoscopic Application

Mann K, Rendl J, Busley R, Sailer B, Seybold S, Hoermann R, Sauerbruch T, Börner W. Systemic iodine absorption during endoscopic application of radiographic contrast agents for endoscopic retrograde cholangiopancreaticography. Eur J Endocrinol 1994;130:498–501. ISSN 0804–4643 Hyperthyroidism induced by contrast agents is a major problem in patients with pre-existing thyroid disease, particularly in patients with functional thyroid autonomy. The present study was undertaken to evaluate whether contrast media applied during endoscopic retrograde cholangiopancreaticography (ERCP) may result in a significant increase of serum iodine levels and thus may be associated with the risk of iodine-induced hyperthyroidism. The courses of serum concentrations of total iodine and free iodide, as well as of urinary iodine excretion, were measured in 15 patients before and up to 21 days after ERCP. During ERCP, the non-ionic contrast medium iopamidol was instilled in amounts resulting in a total iodine load of 57.4 ± 22.8 mmol (7.3 ± 2.9 g). In all patients, ERCP resulted in a highly significant increase in serum levels of total iodine from 0.8±0.5 to 85.2 ± 116.9 μmol/l 4 h after application of the contrast agent. In parallel, serum iodide levels were raised from 0.06 ± 0.04 to 5.42 ± 6.09 μmol/l and urinary iodine excretion from 71.1 ± 35.7 μmol/mol creatinine to 621 620.9 ± 636 492.2 μmol/mol creatinine. Peak concentrations of serum iodine are well related to the total amount of iodine applied (p < 0.05). During follow-up, iodine levels returned to preexposure levels within 2–3 weeks. Levels of thyrotropin, free thyroxine, and free triiodothyronine remained unchanged during the follow-up period. In conclusion, endoscopic application of iodinated contrast agents during ERCP leads to significant increases of serum levels of total iodine and free iodide and of urinary iodine excretion. Therefore, patients with underlying thyroid disease may be at risk to develop iodine-induced hyperthyroidism. Klaus Mann, Dept. of Internal Medicine II. Klinikum Grosshadern, Marchionistr. 15, 81377 Munich, Germany

Rezidivrisiko nach thyreostatischer Behandlung immunogener und nicht-immunogener Hyperthyreosen

1990 ◽  
Vol 29 (01) ◽  
pp. 1-6 ◽  
Author(s):  
E. Voth ◽  
N. Dickmann ◽  
H. Schicha ◽  
D. Emrich
Keyword(s):  
Relapse Rate ◽  
Urinary Iodine ◽  
Young Patients ◽  
Antithyroid Drugs ◽  
Urinary Iodine Excretion ◽  
Old Patients ◽  
Primary Disease ◽  
Iodine Excretion ◽  
Immunogenic Hyperthyroidism

Data of 196 patients treated for hyperthyroidism exclusively with antithyroid drugs were analyzed retrospectively concerning the relapse rate within a follow-up period of four years. Patients were subdivided for primary or recurrent disease, and for immunogenic or non-immunogenic hyperthyroidism, respectively. In immunogenic as well as in non-immunogeriic hyperthyroidism, the relapse rate was significantly lower for patients with primary disease (35% and 52%, respectively) compared to those with recurrent hyperthyroidism (82%, p <0.001 and 83%, p <0.001, respectively). In patients with primary disease, clinical, biochemical and scintigraphic parameters were tested with respect to their capability of predicting a relapse. For immunogenic hyperthyroidism the highest relapse rates were observed in young patients and in those with large goitres, whereas for non-immunogenic hyperthyroidism they were highest in old patients, in those with nodular goitres and in those without an increased urinary iodine excretion at the time of diagnosing hyperthyroidism.

Influence of Radioiodine Therapy on Urinary Iodine Excretion

1998 ◽  
Vol 37 (03) ◽  
pp. 107-112 ◽  
Author(s):  
I. Lauer ◽  
M. Bähre ◽  
E. Richter ◽  
B. Melier
Keyword(s):  
Time Course ◽  
Radioiodine Therapy ◽  
Urinary Iodine ◽  
Target Volume ◽  
Urinary Iodine Excretion ◽  
Urinary Creatinine ◽  
Iodine Excretion ◽  
Kinetics Of ◽  
Persistent Elevation ◽  
Benign Thyroid

Summary Aim: In 214 patients with benign thyroid diseases the time-course of urinary iodine excretion (UIE) was investigated in order to identify changes after radioiodine therapy (RITh). Method: UIE was measured photometrically (cerium-arsenite method) and related to urinary creatinine on the first and last day of the radioiodine test and then three days, seven days, four weeks, and six months after 1311 administration. Results: As compared with the level found immediately before radioiodine therapy, median UIE had almost doubled four weeks after therapy and was still significantly elevated six months after therapy. This increase correlated significantly with the target volume as measured by scintigraphy and sonography. Conclusions: The persistent elevation of UIE for months after RITh is a measure of treatment-induced damage to thyrocytes. Therefore, in view of the unfavourable kinetics of iodine that follow it, RITh should if possible be given via a single-dose regime.

Sign in / Sign up

Export Citation Format

Share Document